Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02882191
Other study ID # CMDOC-0022
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date November 2016
Est. completion date November 12, 2020

Study information

Verified date April 2022
Source Sebela Pharmaceuticals Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effectiveness, device placement, safety, and tolerability of LevoCept to support commencing a Phase III Clinical Study


Description:

Study Design: Prospective, multi-center, single-arm, open-label, Phase II clinical study Approximately 250 subjects will be enrolled at about 14 centers in the US. Study Population: Pre-menopausal women ages 18 - 40, at risk for pregnancy, who are interested in using only this intrauterine contraceptive for birth control will be eligible for this study. Subjects must provide written informed consent and meet the study subject selection criteria without any exclusions as outlined in the Clinical Investigation Plan (CIP). Primary Effectiveness Outcome: The primary outcome measure is effectiveness, evaluated as the absence of pregnancy during LevoCept use. Safety and other outcome measures include: Study Device Placement: - Ease of placement - Placement success Safety: - Serious Adverse Events - Adverse Events Tolerability: - Bleeding and spotting patterns - Discontinuation rate and reasons for discontinuation


Recruitment information / eligibility

Status Completed
Enrollment 279
Est. completion date November 12, 2020
Est. primary completion date July 17, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Between 18-40 years of age at the time of study initiation; 1.1 Enrollment will be targeted for 225 subjects aged 18-35 (for safety and effectiveness analyses) and an additional 25 subjects aged 36-40 (for safety only) (note: all subjects will be included in the analysis for device placement and tolerability); 2. Pre-menopausal, as determined by regular menstrual cycle (28 ± 7 days) for the last 3 months; 2.1 Based on patient history, when not on hormonal contraceptives; 3. Sexually active with a male partner who has not had a vasectomy; 4. Reasonably expected to have to coitus at least once monthly during the study period. 5. In a mutually monogamous relationship of at least 3-6 months duration; 6. Seeking to avoid pregnancy for the next 12 months; 7. Willing to use the study device as the sole form of contraception; 8. Willing to accept a risk of pregnancy; 9. Normal PAP or ASC-US with negative high risk HPV test result within the appropriate screen timeframe, and prior to LevoCept insertion; 10. Able and willing to comply with all study tests, procedures, assessment tools and follow-up; and 11. Able and willing to provide and document informed consent and Authorization for Release of Protected Health Information (PHI). Exclusion Criteria: 1. Known or suspected pregnancy; or at risk for pregnancy from unprotected intercourse earlier in current cycle 2. Subject who anticipates separation from her partner for more than 1 cycle within the next 12 months; 3. A previously inserted IUD that has not been removed by the time LevoCept is placed; 4. History of previous IUD complications, such as perforation, expulsion, infection (pelvic inflammatory disease) or pregnancy with IUD in place.; 5. Injection of hormonal contraceptive (e.g., Depo-Provera) within the last 10 months; 5.1 Must have had 2 normal menstrual cycles since the last injection; 6. Planned use of any non-contraceptive estrogen, progesterone or testosterone any time during the 12 months of study participation; 7. Postpartum, prior to a minimum of 6 weeks and complete uterine involution; 8. Exclusively breastfeeding before return of menses; Lactating women will be excluded unless they have had have had two normal menstrual periods prior to enrollment. 8.1 Must have had 2 normal spontaneous menstrual cycles since delivery 9. Unexplained abnormal uterine bleeding (suspicious for serious condition), before evaluation; Immediately post-septic abortion or puerperal sepsis; 10. Severely heavy or painful menstrual bleeding; 11. Suspected or known cervical, uterine or ovarian cancer, or unresolved clinically significant abnormal pap smear requiring evaluation or treatment. 12. Any history of gestational trophoblastic disease with or without detectable elevated ß-hCG levels, or related malignant disease without an intervening normal pregnancy; 13. Any congenital or acquired uterine anomaly that may complicate IUD placement, such as: 13.1 Submucosal uterine leiomyoma 13.2 Asherman's syndrome 13.3 Pedunculated polyps 13.4 Bicornuate uterus 13.5 Didelphus or uterine septa 14. Any distortions of the uterine cavity (e.g. fibroids), in the opinion of the investigator, likely to cause issues during insertion, retention or removal of the IUD; 15. Known anatomical abnormalities of the cervix such as severe cervical stenosis, prior trachelectomy or extensive conization that, in the opinion of the investigator would prevent cervical dilation and study device placement; 16. Current or recent (within the last 3 months) untreated acute cervicitis or vaginitis; 17. Known or suspected breast cancer or other progestin-sensitive cancer now or in the past; 18. Known acute liver disease or liver tumor; 19. Subjects who have an established immunodeficiency; 20. High risk for STDs (e.g., multiple sexual partners); 21. Known or suspected HIV infection or clinical AIDS; 22. Known intolerance or allergy to any component of the LevoCept system; including nickel, silicone or tantalum; 23. Subject had LevoCept placed previously or had 2 attempts at placement; 24. Known or suspected alcohol or drug abuse within 12 months prior to the screening visit; 25. Any general health or behavioral condition that, in the opinion of the Investigator, could represent an increased risk for the subject or would render the subject less likely to provide the needed study information. 26. Subject is currently participating or has participated in another clinical study involving another investigational agent within 30 days of the planned LevoCept insertion date or is planning participation in another clinical trial with an investigational agent within 52 weeks (visit 6) after insertion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LevoCept
placement of LevoCept IUD

Locations

Country Name City State
United States Emory University School of Medicine Gynecology/Obstetrics Atlanta Georgia
United States University Of Colorado Department of Obstetrics & Gyncology Aurora Colorado
United States Essential Access Health-Berkeley Berkeley California
United States University of Cincinnati Physicians Company, Inc Cincinnati Ohio
United States Ohio State University Columbus Ohio
United States Advanced Research Associates Corpus Christi Texas
United States Kapiolani Medical Center for Women and Children Honolulu Hawaii
United States Essential Access Health-Los Angeles Los Angeles California
United States Columbia University Medical Center New York New York
United States Healthcare Clinical Data, Inc. North Miami Florida
United States Clinical Research of Philadelphia, LLC Philadelphia Pennsylvania
United States Hospital of the University of Pennsylvania Philadelphia Pennsylvania
United States Oregon Health & Science University Portland Oregon
United States University of California Davis Health System Department of Obstetrics and Gynecology Sacramento California
United States University of Utah Healthcare Health Sciences Center Salt Lake City Utah
United States Seattle Women's: Health, Research, Gynecology Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Sebela Women's Health Inc. Synteract, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary absence of pregnancy during LevoCept use 12 months
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A